Intelligence / Healthtech / De Novo Grants / Cardiosense, Inc.
Approvalsnovel device granted (FDA De Novo)22 May 2026
Cardiosense, Inc.
22 May 2026: Novel device granted (FDA De Novo) · PCWP Analysis Software. Recorded in the openFDA device 510(k) (De Novo decisions).
- Granted
- 22 May 2026
- Device
- PCWP Analysis Software
- Specialty
- Cardiovascular
- Product Code
- SIF
- Country
- United States
- Location
- Chicago, IL
- Submitted
- 2025-11-17
- Reference
- DEN250057
What this signal means
A De Novo grant creates a new device category: reimbursement coding, distribution, clinical evidence, manufacturing scale-up and sales hires follow.
- 2 added in the 30 days to 19 Nov 2026.
- Neurology leads (10); 29% went to makers outside the US.
Reach them with AOS
Find the decision makers at Cardiosense, Inc.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.
Across AOS Research
Other records for Cardiosense, Inc. in our registers.
More in Cardiovascular
De Novo Grants
29 SeptBridgeSource Medical Corporationnovel device granted (FDA De Novo) · SmartRead(TM) Medical Device Identifier (4100)Approvals28 JulCaristo Diagnostics, Ltd.novel device granted (FDA De Novo) · CaRi-HeartApprovals17 AprHjarta Care, LLCnovel device granted (FDA De Novo) · XplantR Explant ToolApprovals29 MayReflow Medical, Inc.novel device granted (FDA De Novo) · Spur Peripheral Retrievable Stent SystemApprovals
Source: openFDA device 510(k) (De Novo decisions), data to 19 Nov 2026. Every De Novo classification FDA granted in the last 24 months: a novel device with no legally marketed predicate, which creates a new device type and product code. AOS shows what the public record says; it does not verify or endorse the company.